{"id":"therapeutic-plasma-exchange","safety":{"commonSideEffects":[{"rate":null,"effect":"Citrate toxicity (hypocalcemia)"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Catheter-related complications"},{"rate":null,"effect":"Allergic reactions to replacement fluid"},{"rate":null,"effect":"Coagulopathy"},{"rate":null,"effect":"Infection at vascular access site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"This procedure involves extracorporeal separation of blood into cellular and plasma components, followed by removal of the patient's plasma (which contains disease-causing factors) and replacement with fresh frozen plasma or albumin. It is used to treat autoimmune and immunological disorders where circulating pathogenic factors contribute to disease pathology, such as certain neurological conditions, vasculitis, and thrombotic microangiopathies.","oneSentence":"Therapeutic plasma exchange removes pathogenic antibodies, immune complexes, and other harmful plasma constituents by separating and replacing the patient's plasma with donor plasma or albumin solution.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:38:25.191Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Autoimmune neurological disorders (e.g., Guillain-Barré syndrome, myasthenia gravis)"},{"name":"Thrombotic thrombocytopenic purpura (TTP)"},{"name":"Vasculitis with severe organ involvement"},{"name":"Certain cases of rapidly progressive glomerulonephritis"}]},"trialDetails":[{"nctId":"NCT03798860","phase":"","title":"Monitoring of Donor-specific Antibodies After Treatment With Immunoglobulins, Plasmapheresis and Rituximab in Lung Transplantation","status":"COMPLETED","sponsor":"Hannover Medical School","startDate":"2018-10-01","conditions":"Lung Transplantation, Donor-specific Anti-human Leukocyte Antigen(HLA) Antibodies","enrollment":340},{"nctId":"NCT07178366","phase":"NA","title":"Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-05-10","conditions":"Acute-on-Chronic Liver Failure (ACLF)","enrollment":56},{"nctId":"NCT07100990","phase":"PHASE3","title":"Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-07-11","conditions":"Optic Neuritis, Myelitis, Myelitis, Transverse","enrollment":382},{"nctId":"NCT05714969","phase":"PHASE2","title":"A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2023-03-21","conditions":"Thrombotic Thrombocytopenic Purpura (TTP)","enrollment":33},{"nctId":"NCT05679401","phase":"PHASE3","title":"A Study With Imlifidase in Anti-GBM Disease","status":"TERMINATED","sponsor":"Hansa Biopharma AB","startDate":"2022-12-22","conditions":"Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome","enrollment":50},{"nctId":"NCT05156710","phase":"PHASE2","title":"BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-06-09","conditions":"Transplant Rejection","enrollment":48},{"nctId":"NCT03286556","phase":"PHASE2","title":"Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2018-09-04","conditions":"Idiopathic Pulmonary Fibrosis, Acute Fatal Form","enrollment":82},{"nctId":"NCT07420296","phase":"PHASE4","title":"Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder","status":"RECRUITING","sponsor":"Tianjin Medical University General Hospital","startDate":"2026-01-01","conditions":"Neuromyelitis Optica Spectrum Disorders (NMOSD)","enrollment":198},{"nctId":"NCT06291025","phase":"NA","title":"Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic Purpura","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2024-04-10","conditions":"Thrombotic Microangiopathies","enrollment":131},{"nctId":"NCT02201576","phase":"PHASE2","title":"Bortezomib in Rejection of Kidney Transplants","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-02-11","conditions":"Chronic Antibody-mediated Transplant Rejection","enrollment":60},{"nctId":"NCT07006532","phase":"NA","title":"Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab","status":"RECRUITING","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2025-01-01","conditions":"Kidney Transplant Rejection","enrollment":50},{"nctId":"NCT03635385","phase":"NA","title":"Comparison of ANCA and Anti-GBM Auto-antibodies Removal Kinetics Between Plasma Exchanges and Immunoadsorption in Patients With ANCA-associated Vasculitis or Anti-GBM Disease","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2019-01-23","conditions":"Kidney Failure, Acute","enrollment":40},{"nctId":"NCT04431999","phase":"PHASE3","title":"Evaluation of a Transfusion Therapy Using Whole Blood in the Management of Coagulopathy in Patients With Acute Traumatic Hemorrhage","status":"COMPLETED","sponsor":"Direction Centrale du Service de Santé des Armées","startDate":"2021-12-04","conditions":"Trauma, Acute Hemorrhage, Coagulopathy","enrollment":200},{"nctId":"NCT05179200","phase":"NA","title":"The Effect of Plasma Donation Frequency on Donor Health","status":"COMPLETED","sponsor":"Sykehuset Innlandet HF","startDate":"2022-01-03","conditions":"Psychological Distress, Protein Deficiency, Inflammation","enrollment":120},{"nctId":"NCT05710770","phase":"NA","title":"Immunoadsorption in Patients With Chronic Fatigue Syndrome Including Patients With Post-COVID-19 CFS","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2023-10-01","conditions":"ME/CFS, Post-COVID ME/CFS","enrollment":66},{"nctId":"NCT07329036","phase":"NA","title":"ALSS - DPMAS and Therapeutic Plasma Exchange (TPE), Its Effect on Primary Coagulation, Inflammation and the Function of Vital Organs in ALF or ACLF","status":"RECRUITING","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2024-04-01","conditions":"Acute Liver Failure","enrollment":25},{"nctId":"NCT06831643","phase":"NA","title":"Standard Volume vs. High Volume Plasma Exchange in Pediatric Acute Liver Failure","status":"RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-02-17","conditions":"Acute Liver Failure","enrollment":40},{"nctId":"NCT07316127","phase":"PHASE2","title":"Immunoadsorption in Autoimmune Long COVID","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2026-01-01","conditions":"Long COVID, Long COVID Syndrome, Long COVID-19 Syndrome","enrollment":70},{"nctId":"NCT05468320","phase":"PHASE3","title":"Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-11-21","conditions":"Thrombotic Thrombocytopenic Purpura","enrollment":51},{"nctId":"NCT05030571","phase":"NA","title":"The Effects of Double Plasma Molecular Adsorption System in Acute on Chronic Liver Failure Patients","status":"RECRUITING","sponsor":"Chulalongkorn University","startDate":"2021-01-01","conditions":"Acute-On-Chronic Liver Failure, Acute on Chronic Hepatic Failure","enrollment":40},{"nctId":"NCT06562803","phase":"NA","title":"Efficacy and Safety of Cytokine Adsorption and Plasma Exchange in Patients With ACLF and Sepsis","status":"RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2024-09-27","conditions":"Acute-On-Chronic Liver Failure, Sepsis","enrollment":60},{"nctId":"NCT03702920","phase":"PHASE3","title":"Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%","status":"TERMINATED","sponsor":"Grifols Therapeutics LLC","startDate":"2019-02-21","conditions":"Acute-On-Chronic Liver Failure","enrollment":275},{"nctId":"NCT05145296","phase":"PHASE2","title":"The Safety/Efficacy Of Daratumumab With Belatacept In Highly HLA-Sensitized Patients Awaiting Kidney Transplantation","status":"TERMINATED","sponsor":"University Hospital, Grenoble","startDate":"2022-01-19","conditions":"Sensitisation, Highly Sensitised Dialysis Patients","enrollment":5},{"nctId":"NCT04742374","phase":"EARLY_PHASE1","title":"Effects of Single Plasma Exchange and Double Filtration Plasmapheresis (DFPP) on Peripheral Lymphocyte Phenotypes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2021-03-12","conditions":"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating","enrollment":8},{"nctId":"NCT07087860","phase":"PHASE2","title":"Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-08-01","conditions":"Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma","enrollment":70},{"nctId":"NCT06798129","phase":"","title":"Effects of Extracorporeal Treatment in Patients With Acute Poisoning","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2015-01-01","conditions":"Poisoning, Extracorporeal Treatment","enrollment":5269},{"nctId":"NCT06483139","phase":"","title":"Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2024-06-01","conditions":"Multiple Myeloma, Light Chain Nephropathy, Acute Kidney Injury","enrollment":450},{"nctId":"NCT07197099","phase":"","title":"Evaluation for Therapeutic Plasma Exchange for Immune Mediated Neurological Disease","status":"RECRUITING","sponsor":"Al-Azhar University","startDate":"2025-01-01","conditions":"Neurological Autoimmune Diseases","enrollment":60},{"nctId":"NCT06453694","phase":"PHASE2","title":"Efgartigimod for the Treatment of Acute Optic Neuritis","status":"RECRUITING","sponsor":"Anastasia Vishnevetsky, MD, MPH","startDate":"2025-08-12","conditions":"Optic Neuritis","enrollment":20},{"nctId":"NCT04057872","phase":"PHASE1","title":"Therapeutic Plasma Exchange in Adult Patients With Severe Sepsis","status":"COMPLETED","sponsor":"Alberta Health Services, Calgary","startDate":"2020-10-21","conditions":"Septic Shock","enrollment":17},{"nctId":"NCT04074187","phase":"PHASE2, PHASE3","title":"A Trial of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-10-21","conditions":"Thrombotic Thrombocytopenic Purpura","enrollment":21},{"nctId":"NCT07182409","phase":"","title":"Efficacy and Safety of Monoclonal Antibody in Acute Phase of Neuromyelitis Optica Spectrum Disorder","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Chongqing Medical University","startDate":"2025-10-01","conditions":"NMOSD","enrollment":40},{"nctId":"NCT06515145","phase":"NA","title":"High-volume Versus Standard Volume Plasma Exchange in Patients With Acute Liver Failure With Cerebral Edema","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-12-01","conditions":"Acute Liver Failure, Cerebral Edema","enrollment":60},{"nctId":"NCT03763643","phase":"EARLY_PHASE1","title":"PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2019-07-01","conditions":"Focal Segmental Glomerulosclerosis","enrollment":21},{"nctId":"NCT03737136","phase":"NA","title":"Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2019-11-01","conditions":"Antibody-mediated Rejection","enrollment":20},{"nctId":"NCT07158463","phase":"","title":"Experience With Therapeutic Plasma Exchange in the Pediatric Nephrology Unit of Sohag University Hospital","status":"RECRUITING","sponsor":"Sohag University","startDate":"2025-08-15","conditions":"Experience With Therapeutic Plasma Exchange in the Pediatric Nephrology Unit","enrollment":25},{"nctId":"NCT06597656","phase":"PHASE1","title":"A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74","status":"TERMINATED","sponsor":"Sarepta Therapeutics, Inc.","startDate":"2024-09-18","conditions":"Duchenne Muscular Dystrophy","enrollment":3},{"nctId":"NCT04751643","phase":"NA","title":"Therapeutic Plasma Exchange to Alleviate Hyperinflammatory Condition During Severe Covid-19 Infections","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2021-04-19","conditions":"Intensive Care Units, ARDS, Human, Covid19","enrollment":21},{"nctId":"NCT06272084","phase":"","title":"Analysis of TPE Treatments With multiFiltratePRO","status":"RECRUITING","sponsor":"Fresenius Medical Care Deutschland GmbH","startDate":"2024-05-22","conditions":"Autoimmune Diseases","enrollment":60},{"nctId":"NCT05093075","phase":"PHASE2","title":"Therapeutic Plasma Exchange in Septic Shock: A Pilot Study","status":"RECRUITING","sponsor":"University of Manitoba","startDate":"2023-06-01","conditions":"Septic Shock","enrollment":80},{"nctId":"NCT05841498","phase":"NA","title":"Immunoadsorption Study Mainz in Adults With Post-COVID Syndrome","status":"COMPLETED","sponsor":"University Medical Center Mainz","startDate":"2023-05-08","conditions":"Post-COVID-19 Syndrome, Post-COVID Syndrome, Post COVID-19 Condition","enrollment":40},{"nctId":"NCT07081126","phase":"NA","title":"Daratumumab for Late Antibody-Mediated Rejection","status":"RECRUITING","sponsor":"University Hospital, Martin","startDate":"2025-07-01","conditions":"Kidney Tansplant, Acute Rejection (AR) of Transplanted Kidney","enrollment":20},{"nctId":"NCT04935177","phase":"PHASE3","title":"Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx","status":"COMPLETED","sponsor":"Hansa Biopharma AB","startDate":"2021-10-14","conditions":"Kidney Transplantation in Highly Sensitized Patients","enrollment":64},{"nctId":"NCT06867991","phase":"PHASE3","title":"Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis","status":"RECRUITING","sponsor":"The First People's Hospital of Changzhou","startDate":"2024-11-08","conditions":"Anti-N-Methyl-D-Aspartate Receptor Encephalitis","enrollment":200},{"nctId":"NCT04581382","phase":"EARLY_PHASE1","title":"Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2020-12-14","conditions":"Melanoma","enrollment":18},{"nctId":"NCT04372615","phase":"PHASE2","title":"The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis","status":"RECRUITING","sponsor":"University of Utah","startDate":"2022-03-30","conditions":"Autoimmune Encephalitis, Encephalitis","enrollment":116},{"nctId":"NCT07042490","phase":"NA","title":"Efficacy and Safety of Plasma Adsorption Combined With EVT for AIS-LVO","status":"NOT_YET_RECRUITING","sponsor":"Yi Yang","startDate":"2025-06-30","conditions":"Acute Ischemic Stroke From Large Vessel Occlusion, Endovascular Thrombectomy","enrollment":100},{"nctId":"NCT03542279","phase":"NA","title":"CPI Combination Therapy for Autoimmune Encephalitis","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2020-11-25","conditions":"Autoimmune Encephalitis","enrollment":70},{"nctId":"NCT06607016","phase":"PHASE2","title":"A Clinical Trial With KJ103 in Anti-GBM Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Bao Pharmaceuticals Co., Ltd.","startDate":"2024-10-21","conditions":"Anti-Glomerular Basement Membrane Disease","enrollment":12},{"nctId":"NCT06922851","phase":"NA","title":"Protein A Immunoadsorption in Dilated Cardiomyopathy (RPIA-DCM)","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-06-04","conditions":"Dilated Cardiomyopathy (DCM)","enrollment":60},{"nctId":"NCT04711850","phase":"","title":"An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR","status":"TERMINATED","sponsor":"Hansa Biopharma AB","startDate":"2021-01-20","conditions":"Kidney Transplant Rejection","enrollment":18},{"nctId":"NCT05004493","phase":"","title":"Biorepository and Registry for Plasma Exchange Patients","status":"RECRUITING","sponsor":"Charles M Knudson","startDate":"2021-07-28","conditions":"Antibody-mediated Rejection, NMO Spectrum Disorder, TTP","enrollment":200},{"nctId":"NCT01350232","phase":"NA","title":"Treatment of Sickle Cell Anemia With Stem Cell Transplant","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2009-09","conditions":"Sickle Cell Anemia, Sickle Cell-hemoglobin C Disease, Sickle Cell-β0-thalassemia","enrollment":2},{"nctId":"NCT04685655","phase":"NA","title":"RescuE pLAsma eXchange in Severe COVID-19","status":"TERMINATED","sponsor":"Heidelberg University","startDate":"2020-01-07","conditions":"Therapeutic Plasma Exchange, Covid19","enrollment":67},{"nctId":"NCT03994783","phase":"PHASE3","title":"Transplant Antibody-Mediated Rejection: Guiding Effective Treatments","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2019-07-17","conditions":"Kidney Transplant Rejection, Antibody-mediated Rejection","enrollment":3},{"nctId":"NCT02915718","phase":"NA","title":"A Clinical Study of Immunoadsorption Therapy for Dilated Cardiomyopathy","status":"COMPLETED","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2016-10","conditions":"Dilated Cardiomyopathy","enrollment":7},{"nctId":"NCT00120263","phase":"NA","title":"Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma","status":"COMPLETED","sponsor":"London Health Sciences Centre","startDate":"1998-09","conditions":"Multiple Myeloma, Acute Renal Failure","enrollment":92},{"nctId":"NCT06382675","phase":"NA","title":"Clinical Performance of the New Plasma Filter PX2 in TPE Treatments","status":"RECRUITING","sponsor":"Fresenius Medical Care Deutschland GmbH","startDate":"2024-07-18","conditions":"Autoimmune Diseases","enrollment":46},{"nctId":"NCT05726825","phase":"NA","title":"Efficacy of Add-on Plasma Exchange As an Adjunctive Strategy Against Septic Shock","status":"RECRUITING","sponsor":"Hannover Medical School","startDate":"2025-02-19","conditions":"Septic Shock","enrollment":274},{"nctId":"NCT06187220","phase":"","title":"Plasma Exchange for Amanita Toxin-induced Acute Liver Failure","status":"COMPLETED","sponsor":"Hannover Medical School","startDate":"2024-01-01","conditions":"Acute Liver Failure","enrollment":111},{"nctId":"NCT06855667","phase":"NA","title":"Efficacy and Safety of Therapeutic Plasma Exchange vs Standard Medical Therapy in Severe Autoimmune Hepatitis.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-03-03","conditions":"Autoimmune Hepatitis","enrollment":50},{"nctId":"NCT06797011","phase":"PHASE2, PHASE3","title":"Efficacy of Plasmapheresis in Patients of Drug-Induced Liver Injury (DILI) With Underlying Chronic Liver Disease","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-01-25","conditions":"Drug Induced Liver Injury, Chronic Liver Disease","enrollment":96},{"nctId":"NCT03887741","phase":"PHASE1","title":"Plasmapheresis Versus Plasma Infusion from Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2021-09-15","conditions":"Mild Cognitive Impairment","enrollment":3},{"nctId":"NCT06697678","phase":"","title":"Risk Prediction Model for Severe Autoimmune Encephalitis","status":"NOT_YET_RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2025-01-01","conditions":"Severe Autoimmune Encephalitis","enrollment":1000},{"nctId":"NCT06571552","phase":"NA","title":"Coagulation Disorders Secondary to Two Plasmapheresis Techniques (Double Filtration Plasmapheresis vs. PFS). Descriptive Pilot Study.","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2024-12-17","conditions":"Hyperfibrinogenemia, Hemostatic Disorder","enrollment":6},{"nctId":"NCT05562960","phase":"NA","title":"Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2023-05-01","conditions":"Amyotrophic Lateral Sclerosis, Plasmapheresis","enrollment":20},{"nctId":"NCT06362967","phase":"PHASE2","title":"The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT","status":"RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2024-05-01","conditions":"High Titers of Anti-HLA Antibody (MFI ≥5000)","enrollment":30},{"nctId":"NCT04881682","phase":"PHASE2","title":"Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"RECRUITING","sponsor":"University of Ulm","startDate":"2023-05-01","conditions":"CIDP","enrollment":20},{"nctId":"NCT05484908","phase":"NA","title":"Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC","status":"RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2022-08-12","conditions":"Immune-Mediated Hepatitis, Liver Failure, Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT04597164","phase":"","title":"Combination of DPMAS and Low Volume PE for Patients With HBV Related ACLF","status":"RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2020-12-22","conditions":"Hepatitis B, Chronic, Acute-On-Chronic Liver Failure","enrollment":200},{"nctId":"NCT06698991","phase":"NA","title":"Daily Versus Alternate Day Plasma Exchange in Wilson Disease With Acute Liver Failure in Children","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2024-11-10","conditions":"Acute Liver Failure, Wilson Disease","enrollment":20},{"nctId":"NCT05068830","phase":"PHASE2","title":"Safety and Efficacy of Plasma Transfusion From Exercise-trained Donors in Patients With Early Alzheimer's Disease","status":"RECRUITING","sponsor":"Norwegian University of Science and Technology","startDate":"2021-09-17","conditions":"Alzheimer Disease","enrollment":60},{"nctId":"NCT04408209","phase":"NA","title":"Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection","status":"COMPLETED","sponsor":"National and Kapodistrian University of Athens","startDate":"2020-04-23","conditions":"COVID-19 Infection","enrollment":60},{"nctId":"NCT04776850","phase":"EARLY_PHASE1","title":"Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-29","conditions":"Beta Thalassemia Major, Sickle Beta 0 Thalassemia, Sickle Beta Plus Thalassemia","enrollment":""},{"nctId":"NCT06652516","phase":"NA","title":"Comparison Between Centrifugation Based and Membrane Based Plasma Exchange","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2023-01-05","conditions":"Therapeutic Plasma Exchange","enrollment":20},{"nctId":"NCT04973488","phase":"NA","title":"Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients","status":"COMPLETED","sponsor":"Novacescu Alexandru","startDate":"2020-07-25","conditions":"COVID-19 Pneumonia, COVID-19 Respiratory Infection, Acute Respiratory Failure","enrollment":38},{"nctId":"NCT04302805","phase":"PHASE3","title":"rATG Versus rATG Combined With Intravenous Immunoglobulin (IVIG) Induction Immunosuppression in HLA Incompatible Transplantation (INHIBIT)","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2020-07-27","conditions":"Kidney Transplantation","enrollment":17},{"nctId":"NCT06534450","phase":"PHASE3","title":"The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dobri Kiprov","startDate":"2022-09-12","conditions":"Aging","enrollment":40},{"nctId":"NCT05214612","phase":"","title":"Predictors and Prognostic Factors of Myasthenia Gravis Outcome","status":"RECRUITING","sponsor":"Assiut University","startDate":"2022-01-01","conditions":"Myasthenia Gravis, Autoimmune Diseases of the Nervous System, Neuromuscular Junction Diseases","enrollment":30},{"nctId":"NCT00953771","phase":"PHASE2","title":"Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)","status":"TERMINATED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2008-10","conditions":"Thrombotic Thrombocytopenic Purpura","enrollment":9},{"nctId":"NCT06355726","phase":"NA","title":"Efficacy of Plasma Exchange Therapy vs Standard Medical Therapy in Severe Alcoholic Hepatitis With High Discriminant Function","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2024-04-09","conditions":"Alcoholic Hepatitis","enrollment":60},{"nctId":"NCT04623255","phase":"PHASE2","title":"Study of Plasma Exchange in Severe COVID-19","status":"COMPLETED","sponsor":"University College, London","startDate":"2020-10-16","conditions":"COVID19","enrollment":23},{"nctId":"NCT06404424","phase":"","title":"Combined Hemoperfusion and Therapeutic Plasma Exchange for Treatment of Patients With Septic Shock","status":"COMPLETED","sponsor":"Efferon JSC","startDate":"2022-05-01","conditions":"Sepsis, Septic Shock","enrollment":82},{"nctId":"NCT04871035","phase":"","title":"Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)","status":"RECRUITING","sponsor":"University of Ulm","startDate":"2021-04-28","conditions":"GBS","enrollment":20},{"nctId":"NCT03477656","phase":"NA","title":"Evaluation of 2 Techniques of Apheresis to Desensitize ABO Incompatible Kidney Transplant Candidates","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2018-05-02","conditions":"Kidney Transplantation","enrollment":30},{"nctId":"NCT06323902","phase":"","title":"Autologous Platelet-rich Plasma as a Treatment for Macular Holes","status":"COMPLETED","sponsor":"Clinica Oftalmologica Paredes","startDate":"2022-10-25","conditions":"Macular Holes, Macular Hole of Left Eye (Disorder), Macular Hole of Right Eye (Disorder)","enrollment":13},{"nctId":"NCT01156922","phase":"PHASE2","title":"B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome","status":"TERMINATED","sponsor":"Haukeland University Hospital","startDate":"2010-06","conditions":"Chronic Fatigue Syndrome, Myalgic Encephalomyelitis","enrollment":8},{"nctId":"NCT03897205","phase":"PHASE2","title":"An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients","status":"COMPLETED","sponsor":"Hansa Biopharma AB","startDate":"2019-04-30","conditions":"Kidney Transplant Rejection","enrollment":30},{"nctId":"NCT06276907","phase":"NA","title":"An Open-label Randomized Controlled Trial Comparing the Role of Therapeutic Plasma-exchange in Ameliorating Secondary Organ Dysfunctions in Patients With ACLF and Develop Biomarkers of Treatment Response","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2024-03-01","conditions":"Acute on Chronic Liver Failure","enrollment":190},{"nctId":"NCT04351438","phase":"","title":"Evaluation of Complication Rates Using Filter vs. Centrifuge and Heparin vs. Citrate Anticoagulation","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2012-01-01","conditions":"Therapeutic Plasma Exchange, Anticoagulant Therapy","enrollment":108},{"nctId":"NCT06234436","phase":"EARLY_PHASE1","title":"Plasma Dilution and Infusion to Improve Cognition in Mild Cognitive Impairment (MCI)","status":"UNKNOWN","sponsor":"Oslo University Hospital","startDate":"2023-12-07","conditions":"Alzheimer Disease","enrollment":10},{"nctId":"NCT02622854","phase":"NA","title":"Plasma Exchange vs Conservative Management in Non-severe Acute Hypertriglyceridemic Pancreatitis","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2016-06","conditions":"Acute Pancreatitis","enrollment":22},{"nctId":"NCT06079827","phase":"","title":"Impact of Therapeutic Plasma Exchange on RNA Biomarker Expression Levels in Alzheimer's Patients","status":"UNKNOWN","sponsor":"MaxWell Clinic, PLC","startDate":"2022-03-22","conditions":"Alzheimer Disease","enrollment":43},{"nctId":"NCT04456413","phase":"PHASE2","title":"Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2020-11-06","conditions":"COVID-19","enrollment":21},{"nctId":"NCT05129904","phase":"","title":"Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint (PADSTONE Study)","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2021-09-15","conditions":"DPMAS Therapy in Liver Disease Patients","enrollment":1300},{"nctId":"NCT04343755","phase":"PHASE2","title":"Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2020-04-09","conditions":"COVID-19","enrollment":52},{"nctId":"NCT05004220","phase":"","title":"Effects of Plasmapheresis on Aging Biomarkers","status":"COMPLETED","sponsor":"Charles University, Czech Republic","startDate":"2021-04-06","conditions":"Aging, Plasmapheresis","enrollment":41},{"nctId":"NCT05543590","phase":"NA","title":"Effect of Plasmapheresis on Clinical Improvement and Biological Parameters of Patients With Long-haul COVID","status":"WITHDRAWN","sponsor":"Hôpital Européen Marseille","startDate":"2023-02","conditions":"Long-Haul COVID-19","enrollment":""},{"nctId":"NCT03772717","phase":"NA","title":"Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"TERMINATED","sponsor":"Emory University","startDate":"2022-02-22","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":2},{"nctId":"NCT05251896","phase":"NA","title":"Plasma-free Replacement in Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Zhongnan Hospital","startDate":"2020-01-01","conditions":"Multiple Myeloma","enrollment":119}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"BACTERAEMIA"},{"count":2,"reaction":"DRUG EFFECTIVE FOR UNAPPROVED INDICATION"},{"count":2,"reaction":"OFF LABEL USE"},{"count":1,"reaction":"DRUG INEFFECTIVE"},{"count":1,"reaction":"DRUG INTERACTION"},{"count":1,"reaction":"HAEMODYNAMIC INSTABILITY"},{"count":1,"reaction":"HYPOCALCAEMIA"},{"count":1,"reaction":"HYPOTENSION"},{"count":1,"reaction":"HYPOXIA"}],"_approvalHistory":[],"publicationCount":2440,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Therapeutic plasma exchanges"],"phase":"phase_3","status":"active","brandName":"Therapeutic plasma exchange","genericName":"Therapeutic plasma exchange","companyName":"Centre Hospitalier St Anne","companyId":"centre-hospitalier-st-anne","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Therapeutic plasma exchange removes pathogenic antibodies, immune complexes, and other harmful plasma constituents by separating and replacing the patient's plasma with donor plasma or albumin solution. Used for Autoimmune neurological disorders (e.g., Guillain-Barré syndrome, myasthenia gravis), Thrombotic thrombocytopenic purpura (TTP), Vasculitis with severe organ involvement.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":6,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}